I agree 120% :) I learned about HZNP from SA. Most important to me was the fact that TW had a proven track record as a sales and marketing specialist who can orchestrate increase of revenues 10+ folds in a relatively short period of time. Admittedly I got in too early. However, SA put on my radar a winner that I followed all the way down to $1.98 at which point and up I increased my original small investment almost 10 folds and brought in my friends. There are plenty of clowns on SA board who post there just to earn penny for each click we made to read their articles (screed). However, one has to have some brain to sort out the truth from a fiction. At least to me SA is a second to none source of new investment ideas.
PB, You are one lucky SOG. I was planning to go to Bali this fall as well. In late eighties and early nineties I traveled to SEA about twenty times. Absolutely love Thailand. Have fun :)
You are correct on both points. Management did say during numerous presentation that a long term strategy for the company is to increase a number of products they represent. I also agree with your second statement. Personally, I do not think that at this stage of the company development it is of paramount importance to find a new drug(s) for management nor for price per share appreciation. If you think that my opinion is a nonsense it is fine. I enjoy your posts nevertheless.
Does anyone notice that at least four trades today were around 50,000 shares? Most likely HZNP is selling authorized shares (as ATM).
On another topic, I doubt that at present management is actively looking for new product since it would be much more prudent for them to pay down debt with annual interest of 17% first.
From Seeking Alpha:
Healthcare upgrades, downgrades, and initiations • 9:03 AM
Myriad Genetics (MYGN) cut to Underperform from Neutral at Credit Suisse. Price target is $20.
Mead Johnson Nutrition (MJN) upgraded to Buy from Neutral at JPMorgan.
Horizon Pharma (HZNP) upgraded to Overweight from Neutral at Piper. Price target is $7.
Opthotech (OPHT) initiated at Overweight by Morgan Stanley. Price target is $56.
Price per share is a combination of upgrade and shorts covering. Short interest is down more than 350K and dropping.
Thanks for taking notes and sharing with everyone. Please correct me if I am wrong, per TS, annualized projected sales at present growth rate are $125M. If that is a case HZNP will do fine without additional debt or shares dilutions and potentially become profitable next year.
Sentiment: Strong Buy
Short interest continue to climb up from this year low on May 31 2013 when it was 4,417,080 up to 5,688,880 ( or 1,271,800 shares increase) as of September 13th. At today's volume of about 400K it will take over 14 days to cover. Let us hope that "smart money" are wrong again.
Sentiment: Strong Buy